{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:39:18Z","timestamp":1786991958069,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jctejournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical & Translational Endocrinology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jcte.2021.100290","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T02:43:54Z","timestamp":1638845034000},"page":"100290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Cystic fibrosis-related diabetes: Prevalence, screening, and diagnosis"],"prefix":"10.1016","volume":"27","author":[{"given":"Swapnil","family":"Khare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Desimone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Kasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcte.2021.100290_b0005","unstructured":"Cystic Fibrosis Foundation Patient Registry. 2019: Bethesda Maryland."},{"key":"10.1016\/j.jcte.2021.100290_b0010","unstructured":"Cystic Fibrosis Foundation Patient Registry. 2013: Bethesda Maryland."},{"issue":"5","key":"10.1016\/j.jcte.2021.100290_b0015","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.2337\/dc06-1576","article-title":"Microvascular complications in cystic fibrosis-related diabetes","volume":"30","author":"Schwarzenberg","year":"2007","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.jcte.2021.100290_b0020","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.jcte.2021.100290_b0025","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jcf.2019.03.007","article-title":"The impact of cystic fibrosis-related diabetes on health-related quality of life","volume":"18","author":"Kwong","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"9","key":"10.1016\/j.jcte.2021.100290_b0030","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/dme.13652","article-title":"Unique challenges of cystic fibrosis-related diabetes","volume":"35","author":"Bridges","year":"2018","journal-title":"Diabet Med"},{"issue":"7006","key":"10.1016\/j.jcte.2021.100290_b0035","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/bmj.311.7006.655","article-title":"Glucose tolerance in patients with cystic fibrosis: five year prospective study","volume":"311","author":"Lanng","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.jcte.2021.100290_b0040","doi-asserted-by":"crossref","unstructured":"Olesen, H.V., et al., Cystic fibrosis related diabetes in Europe: Prevalence, risk factors and outcome; Olesen et al. J Cyst Fibros, 2020. 19(2): p. 321-327.","DOI":"10.1016\/j.jcf.2019.10.009"},{"issue":"2","key":"10.1016\/j.jcte.2021.100290_b0045","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jcf.2019.07.010","article-title":"The association of pediatric cystic fibrosis-related diabetes screening on clinical outcomes by center: A CF patient registry study","volume":"19","author":"Franck Thompson","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcte.2021.100290_b0050","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1164\/rccm.201403-0576OC","article-title":"Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex","volume":"191","author":"Lewis","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jcte.2021.100290_b0055","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jpeds.2004.12.039","article-title":"Epidemiology of cystic fibrosis-related diabetes","volume":"146","author":"Marshall","year":"2005","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.jcte.2021.100290_b0060","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jcf.2019.04.015","article-title":"Incidence and risk factors of paediatric cystic fibrosis-related diabetes","volume":"18","author":"Perrem","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcte.2021.100290_b0065","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1055\/s-0035-1547347","article-title":"Lung transplantation for cystic fibrosis: results, indications, complications, and controversies","volume":"36","author":"Lynch","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jcte.2021.100290_b0070","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1399-0012.2005.00420.x","article-title":"Incidence and prevalence of diabetes mellitus in patients with cystic fibrosis undergoing lung transplantation before and after lung transplantation","volume":"19","author":"Hadjiliadis","year":"2005","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jcte.2021.100290_b0075","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/j.jcf.2019.08.019","article-title":"Endocrine complications after solid-organ transplant in cystic fibrosis","volume":"18","author":"Sidhaye","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcte.2021.100290_b0080","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"9","key":"10.1016\/j.jcte.2021.100290_b0085","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/BF01957574","article-title":"Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis","volume":"151","author":"Lanng","year":"1992","journal-title":"Eur J Pediatr"},{"issue":"1","key":"10.1016\/j.jcte.2021.100290_b0090","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0022-3476(98)70171-4","article-title":"Abnormal glucose metabolism in cystic fibrosis","volume":"133","author":"Moran","year":"1998","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.jcte.2021.100290_b0095","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0022-3476(88)80315-9","article-title":"Diabetes mellitus associated with cystic fibrosis","volume":"112","author":"Finkelstein","year":"1988","journal-title":"J Pediatr"},{"issue":"12","key":"10.1016\/j.jcte.2021.100290_b0100","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes association and a clinical practice guideline of the cystic fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcte.2021.100290_b0105","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jcf.2019.08.016","article-title":"Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis","volume":"18","author":"Granados","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcte.2021.100290_b0110","doi-asserted-by":"crossref","unstructured":"International Association of, D., et al., International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care, 2010. 33(3): p. 676-82.","DOI":"10.2337\/dc09-1848"},{"issue":"2","key":"10.1016\/j.jcte.2021.100290_b0115","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc10-1604","article-title":"Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis","volume":"34","author":"Brodsky","year":"2011","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.jcte.2021.100290_b0120","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jcf.2015.03.001","article-title":"Characterization of patients with cystic fibrosis presenting an indeterminate glucose tolerance (INDET)","volume":"15","author":"Coriati","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcte.2021.100290_b0125","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/MOP.0000000000000251","article-title":"Advances in the detection and management of cystic fibrosis related diabetes","volume":"27","author":"Hameed","year":"2015","journal-title":"Curr Opin Pediatr"},{"issue":"2","key":"10.1016\/j.jcte.2021.100290_b0130","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jcf.2020.08.020","article-title":"Delayed glucose peak and elevated 1-hour glucose on the oral glucose tolerance test identify youth with cystic fibrosis with lower oral disposition index","volume":"20","author":"Tommerdahl","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcte.2021.100290_b0135","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1108\/IJHCQA-05-2014-0059","article-title":"Improving screening for diabetes in cystic fibrosis","volume":"28","author":"Abdulhamid","year":"2015","journal-title":"Int J Health Care Qual Assur"},{"issue":"2","key":"10.1016\/j.jcte.2021.100290_b0140","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1542\/peds.2012-4029","article-title":"Improving screening for cystic fibrosis-related diabetes at a pediatric cystic fibrosis program","volume":"132","author":"Kern","year":"2013","journal-title":"Pediatrics"},{"issue":"Suppl 1","key":"10.1016\/j.jcte.2021.100290_b0145","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.2337\/dc10-S062","article-title":"Diagnosis and classification of diabetes mellitus","volume":"33","author":"American Diabetes","year":"2010","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.jcte.2021.100290_b0150","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2016.02.005","article-title":"Glycated hemoglobin cannot yet be proposed as a screening tool for cystic fibrosis related diabetes","volume":"15","author":"Boudreau","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcte.2021.100290_b0155","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jcf.2015.03.013","article-title":"HbA1c as a screening tool for cystic fibrosis related diabetes","volume":"15","author":"Burgess","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcte.2021.100290_b0160","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jcf.2005.09.001","article-title":"Relationship between glycosylated haemoglobin and mean plasma glucose concentration in cystic fibrosis","volume":"5","author":"Brennan","year":"2006","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcte.2021.100290_b0165","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2337\/dc17-2419","article-title":"Hemoglobin A1c Accurately Predicts Continuous Glucose Monitoring-Derived Average Glucose in Youth and Young Adults With Cystic Fibrosis","volume":"41","author":"Chan","year":"2018","journal-title":"Diabetes Care"},{"issue":"9133","key":"10.1016\/j.jcte.2021.100290_b0170","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0140-6736(98)04055-0","article-title":"Diabetes in older adults: comparison of 1997 American Diabetes Association classification of diabetes mellitus with 1985 WHO classification","volume":"352","author":"Wahl","year":"1998","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jcte.2021.100290_b0175","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.2337\/dc10-1279","article-title":"Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.jcte.2021.100290_b0180","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1262-3636(07)70189-1","article-title":"Diabetes: a major co-morbidity of cystic fibrosis","volume":"31","author":"Costa","year":"2005","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/j.jcte.2021.100290_b0185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jcf.2017.05.010","article-title":"The use of fructosamine in cystic fibrosis-related diabetes (CFRD) screening","volume":"17","author":"Lam","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcte.2021.100290_b0190","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4158\/EP09149.OR","article-title":"Lack of correlation between 1,5-anhydroglucitol assay and oral glucose tolerance test in patients with cystic fibrosis","volume":"16","author":"Kinnaird","year":"2010","journal-title":"Endocr Pract"},{"issue":"8","key":"10.1016\/j.jcte.2021.100290_b0195","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/pedi.12914","article-title":"Screening for cystic fibrosis-related diabetes and prediabetes: Evaluating 1,5-anhydroglucitol, fructosamine, glycated albumin, and hemoglobin A1c","volume":"20","author":"Tommerdahl","year":"2019","journal-title":"Pediatr Diabetes"},{"issue":"7","key":"10.1016\/j.jcte.2021.100290_b0200","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2337\/dc10-2289","article-title":"Hyperglycemia and death in cystic fibrosis-related diabetes","volume":"34","author":"Adler","year":"2011","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.jcte.2021.100290_b0205","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jcf.2018.03.008","article-title":"Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline","volume":"17","author":"Chan","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcte.2021.100290_b0210","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jcf.2019.08.025","article-title":"Continuous glucose monitoring in cystic fibrosis \u2013 A practical guide","volume":"18","author":"Chan","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcte.2021.100290_b0215","first-page":"860","article-title":"Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy","volume":"90","author":"Rolon","year":"2001","journal-title":"Acta Paediatr"},{"issue":"6","key":"10.1016\/j.jcte.2021.100290_b0220","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2337\/dc08-1925","article-title":"Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study","volume":"32","author":"O'Riordan","year":"2009","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.jcte.2021.100290_b0225","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/EJE-09-1020","article-title":"Abnormal glucose tolerance in children with cystic fibrosis: the predictive role of continuous glucose monitoring system","volume":"162","author":"Schiaffini","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.jcte.2021.100290_b0230","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jcf.2021.01.002","article-title":"Abnormal glucose tolerance and lung function in children with cystic fibrosis","volume":"20","author":"Elidottir","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcte.2021.100290_b0235","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/jama.2016.19975","article-title":"Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial","volume":"317","author":"Beck","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jcte.2021.100290_b0240","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00592-014-0643-6","article-title":"The use of continuous glucose monitoring systems in a pediatric population with type 1 diabetes mellitus in real-life settings: the AWeSoMe Study Group experience","volume":"52","author":"Rachmiel","year":"2015","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.jcte.2021.100290_b0245","doi-asserted-by":"crossref","unstructured":"Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study, G., Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. Diabetes Care, 2010. 33(1): p. 17-22.","DOI":"10.2337\/dc09-1502"},{"issue":"8","key":"10.1016\/j.jcte.2021.100290_b0250","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"}],"container-title":["Journal of Clinical & Translational Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214623721000429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214623721000429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:59:12Z","timestamp":1762005552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214623721000429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":50,"alternative-id":["S2214623721000429"],"URL":"https:\/\/doi.org\/10.1016\/j.jcte.2021.100290","relation":{},"ISSN":["2214-6237"],"issn-type":[{"value":"2214-6237","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cystic fibrosis-related diabetes: Prevalence, screening, and diagnosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical & Translational Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcte.2021.100290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100290"}}